Andere Sprachen Imunon, Inc.

Aktien

A3DWEJ

US15117N6022

IMNN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 24.05.2024			% 5 Tage	% 1. Jan.
1,51 ^USD	+4,14 %		+7,86 %	+122,06 %

13.05.	Transcript : Imunon, Inc., Q1 2024 Earnings Call, May 13, 2024
08.05.	IMUNON, Inc. ernennt Stacy R. Lindborg zum Chief Executive Officer mit Wirkung zum 13. Mai 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Imunon : Management Change/Compensation - Form 8-K	20.05.
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting	15.05.
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study	13.05.
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update	13.05.
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO	08.05.
IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024	08.05.
IMUNON, Inc. Appoints Stacy R. Lindborg as President, Effective May 13, 2024	08.05.
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024	06.05.
Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine	18.04.
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine	18.04.
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101	18.04.
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101	18.04.
IMUNON Reports Compliance with Nasdaq Listing Requirements	11.04.
Top Midday Gainers	28.03.
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
IMUNON Reports 2023 Financial Results and Provides Business Update	28.03.
North American Morning Briefing : Stocks Set for -2-	28.03.
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses	25.03.
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024	21.03.
IMUNON Files IND Application to Begin Human Testing of IMNN-101	13.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Imunon, Inc.

Aktien

A3DWEJ

US15117N6022

IMNN

Andere Sprachen

Filter